Relmada Therapeutics (RLMD) Liabilities and Shareholders Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $235.4 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 750.32% year-over-year to $235.4 million in Q1 2026; TTM through Mar 2026 was $365.4 million, a 82.45% increase from a year earlier, with the FY2025 full-year figure at $94.0 million, up 105.17% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $235.4 million, up from $94.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RLMD reached as high as $235.4 million in Q1 2026 and fell as low as $14.9 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $111.5 million across 5 years, with a median of $97.6 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity slumped 73.3% in 2025 and jumped 750.32% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $152.9 million in 2022, then tumbled by 36.2% to $97.6 million in 2023, then plunged by 53.03% to $45.8 million in 2024, then jumped by 105.17% to $94.0 million in 2025, then jumped by 150.38% to $235.4 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $235.4 million in Q1 2026, $94.0 million in Q4 2025, and $14.9 million in Q3 2025.